Consensus statement on the use of biosimilar drugs in immune-mediated diseases in Spain
Copyright © 2022 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved..
OBJECTIVE: To improve knowledge about biosimilar medicines and to generate a consensus framework on their use.
METHODS: Qualitative study. A multidisciplinary group of experts in biosimilar medicines was established (1dermatologist, 1hospital pharmacist, 1rheumatologist, and 1gastroenterologist) who defined the sections and topics of the document. A narrative literature review was performed in Medline to identify articles on biosimilar medicines. Systematic reviews, controlled, pre-clinical, clinical, and real-life studies were selected. Based on the results of the review, several general principles and recommendations were generated. The level of agreement was tested in a Delphi that was extended to 66 health professionals who voted from 1 (totally disagree) to 10 (totally agree). Agreement was defined if at least 70% of the participants voted ≥7.
RESULTS: The literature review included 555 articles. A total of 10 general principles and recommendations were voted upon. All reached the level of agreement established. The document includes data on the main characteristics of biosimilar medicines (definition, development, approval, indication extrapolation, interchangeability, financing, and traceability); published evidence (biosimilarity, efficacy, effectiveness, safety, immunogenicity, efficiency, switch); barriers and facilitators to its use; and data on information for patients.
CONCLUSIONS: Authorized biosimilar medicines meet all the characteristics of quality, efficacy, and safety. They also significantly help improve patient access to biological therapies and contribute to health system sustainability.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Reumatologia clinica - 19(2023), 8 vom: 07. Okt., Seite 446-454 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Monte-Boquet, Emilio [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 01.11.2023 Date Revised 01.11.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.reumae.2022.12.004 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36298848X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36298848X | ||
| 003 | DE-627 | ||
| 005 | 20231226092406.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.reumae.2022.12.004 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1209.xml |
| 035 | |a (DE-627)NLM36298848X | ||
| 035 | |a (NLM)37805258 | ||
| 035 | |a (PII)S2173-5743(23)00073-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Monte-Boquet, Emilio |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Consensus statement on the use of biosimilar drugs in immune-mediated diseases in Spain |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.11.2023 | ||
| 500 | |a Date Revised 01.11.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved. | ||
| 520 | |a OBJECTIVE: To improve knowledge about biosimilar medicines and to generate a consensus framework on their use | ||
| 520 | |a METHODS: Qualitative study. A multidisciplinary group of experts in biosimilar medicines was established (1dermatologist, 1hospital pharmacist, 1rheumatologist, and 1gastroenterologist) who defined the sections and topics of the document. A narrative literature review was performed in Medline to identify articles on biosimilar medicines. Systematic reviews, controlled, pre-clinical, clinical, and real-life studies were selected. Based on the results of the review, several general principles and recommendations were generated. The level of agreement was tested in a Delphi that was extended to 66 health professionals who voted from 1 (totally disagree) to 10 (totally agree). Agreement was defined if at least 70% of the participants voted ≥7 | ||
| 520 | |a RESULTS: The literature review included 555 articles. A total of 10 general principles and recommendations were voted upon. All reached the level of agreement established. The document includes data on the main characteristics of biosimilar medicines (definition, development, approval, indication extrapolation, interchangeability, financing, and traceability); published evidence (biosimilarity, efficacy, effectiveness, safety, immunogenicity, efficiency, switch); barriers and facilitators to its use; and data on information for patients | ||
| 520 | |a CONCLUSIONS: Authorized biosimilar medicines meet all the characteristics of quality, efficacy, and safety. They also significantly help improve patient access to biological therapies and contribute to health system sustainability | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Biosimilar medicine | |
| 650 | 4 | |a Delphi | |
| 650 | 4 | |a Enfermedades inmunomediadas | |
| 650 | 4 | |a Extrapolación | |
| 650 | 4 | |a Extrapolation | |
| 650 | 4 | |a Immune-mediated diseases | |
| 650 | 4 | |a Intercambiabilidad | |
| 650 | 4 | |a Interchangeability | |
| 650 | 4 | |a Medicamento biosimilar | |
| 650 | 7 | |a Biosimilar Pharmaceuticals |2 NLM | |
| 700 | 1 | |a Florez, Ángeles |e verfasserin |4 aut | |
| 700 | 1 | |a Alcaín Martínez, Guillermo José |e verfasserin |4 aut | |
| 700 | 1 | |a Sellas, Agustí |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Reumatologia clinica |d 2011 |g 19(2023), 8 vom: 07. Okt., Seite 446-454 |w (DE-627)NLM213092891 |x 2173-5743 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2023 |g number:8 |g day:07 |g month:10 |g pages:446-454 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.reumae.2022.12.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2023 |e 8 |b 07 |c 10 |h 446-454 | ||